Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012

     Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012

Company To Discuss Recent Obesity Therapeutics Market Research and Provide a
Light Study Update at Event

PR Newswire

SAN DIEGO, Dec. 4, 2012

SAN DIEGO, Dec. 4, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq:
OREX), a biopharmaceutical company focused on the treatment of obesity, today
announced that the Company will provide details of obesity therapeutics market
research including the results of surveys of 1,000 physicians and 6,000
patients during an Analyst Day event on December 18, 2012. The Company will
also provide an update to the Contrave® Light Study and discuss U.S. and EU
regulatory planning.

The Analyst Day event will be held in New York City on December 18, 2012 from
9 a.m. to 12 p.m. Eastern Time.

While attendance in person is by invitation only, Orexigen will webcast the
Analyst Day presentations. The webcast can be accessed live on the Investor
Relations section of the Orexigen website at www.orexigen.com and will be
archived for 14 days following the call.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave®, which
has completed Phase III clinical trials and for which a New Drug Application
has been submitted and reviewed by the FDA. The Company has also reached
agreement with the FDA on a Special Protocol Assessment (SPA) for the Light
Study, the Contrave cardiovascular outcomes trial. The Company's other product
candidate, Empatic™, has completed Phase II clinical trials. Further
information about the Company can be found at www.orexigen.com.


Source:
Orexigen Therapeutics
McDavid Stilwell
Vice President, Corporate Communications & Business Development
858-875-8600

SOURCE Orexigen Therapeutics, Inc.

Website: http://www.orexigen.com
 
Press spacebar to pause and continue. Press esc to stop.